IMS Health purchased for $5.2 billion

Share this article:
Marketing research giant IMS Health will be acquired by private equity firm TPG Capital and the Canadian Pension Plan Investment Board, a Toronto-based investment management organization, for $5.2 billion.

The acquisition also covers IMS Health's outstanding debt, equaling roughly $1.3 billion as of September 30, according to third quarter reports. Debt financing will be provided by an amalgam of Goldman, Sachs & Co. affiliates, according to a release.

A spokesperson for IMS Health said the company will continue operating under its flagship name – IMS Health – adding that the transaction reflects a confidence in the company's business model.

IMS Health “will continue our focus on expanding into new markets, further improving the quality and depth of offerings we deliver to our clients, and playing a bigger role in the healthcare market,” David Carlucci, IMS chairman and CEO, said in a statement.

The acquisition, subject to the approval of IMS shareholders, regulatory approvals and customary closing conditions, is expected to be completed by the end of the first quarter, 2010.

IMS Health's third quarter revenue was $540.8 million – down from $573.7 during the same period last year. However, that figure represents a 3% growth over second quarter earnings in 2009, according to third quarter reports.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...